# US 2012/0251527 A1 · Podocyte specific assays and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251527 A1
- Document ID: US20120251527A1
- Status: Published application
- Kind: A1
- Application number: 13/508,088
- Filed: 2010-11-08
- Published: 2012-10-04
- Earliest claimed: 2009-11-06
- Assignees: University of Miami
- Inventors: Jochen Reiser
- Web page: https://patentgrep.com/patent/US20120251527A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C12Q 1/42: involving phosphatase
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Compositions are directed to the treatment of kidney diseases in a cell-specific manner. Methods of treating kidney diseases comprise the use of the compositions. Assays for identification of further compounds are provided.

## Claims

### Claim 1

A method of measuring or quantifying calcineurin activity in vitro or in vivo comprising:
transforming a cell with a reporter construct, wherein the reporter construct comprising a polynucleotide encoding a nuclear factor of activated T cells (NFAT); a selectable marker and a reporter gene;
measuring NFAT activity in the sample;
correlating NFAT activity to calcineurin activity; and;
measuring or quantifying calcineurin activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the reporter gene is operably linked to the NFAT polynucleotide comprising an NFAT response element.

### Claim 3 (depends on 2)

The method of claim 2, wherein the reporter gene is under control of the NFAT response element.

### Claim 4 (depends on 1)

The method of claim 1, wherein NFAT phosphorylation or dephosphorylation state is a measure of NFAT activity.

### Claim 5 (depends on 1)

The method of claim 1, wherein NFAT is localized in different intra-cellular compartments depending on NFAT phosphorylation states.

### Claim 6 (depends on 1)

The method of claim 1, wherein phosphorylated NFAT is detected in podocyte cytoplasm and dephosphorylated NFAT is detected in podocyte nuclei.

### Claim 7 (depends on 1)

The method of claim 1, wherein NFAT activity is detected by a reporter assay.

### Claim 8 (depends on 2)

The method of claim 2, wherein the reporter gene is a luciferase gene or mutants thereof.

### Claim 9

A reporter construct comprising: polynucleotide encoding a nuclear factor of activated T cells (NFAT), fragments or mutants thereof; a selectable marker and a reporter gene.

### Claim 10 (depends on 9)

The reporter construct of claim 9, wherein the reporter gene comprising at least one wild-type luciferase, luciferase mutants or combinations thereof.

### Claim 11 (depends on 9)

The reporter construct of claim 9, wherein the polynucleotide encoding a nuclear factor of activated cells (NFAT) comprises an NFAT response element.

### Claim 12 (depends on 11)

The reporter construct of claim 11, wherein the reporter gene is under control of the NFAT response element

### Claim 13 (depends on 9)

An isolated cell comprising the reporter construct of claim 9.

### Claim 14

A method of diagnosing an immune-related disease or condition in a patient comprising:
obtaining a sample from a patient and measuring NFAT activity in the sample;
correlating NFAT activity to calcineurin activity; and,
diagnosing an immune-related disease or condition in a patient.

### Claim 15 (depends on 14)

The method of claim 14, wherein the immune-related disease comprising: acute immune diseases, chronic immune diseases, autoimmune diseases, inflammation, tissue or organ transplant graft rejections or graft-versus-host disease.

### Claim 16

A method of diagnosing kidney disease or condition in a patient comprising: obtaining a sample from a patient and measuring NFAT activity in the sample;
correlating NFAT activity to calcineurin activity; and,
diagnosing kidney disease or condition in a patient.

### Claim 17

A method of diagnosing cancer in a patient comprising: obtaining a sample from a patient and measuring NFAT activity in the sample;
correlating NFAT activity to calcineurin activity; and,
diagnosing cancer in a patient.

### Claim 18

A method of screening and identifying novel therapeutic compounds comprising:
contacting an NFAT molecule or a cell comprising a reporter construct, wherein the reporter construct comprising a polynucleotide encoding a nuclear factor of activated T cells (NFAT), a selectable marker and a reporter gene;
measuring NFAT activity in the presence or absence of the compound;
correlating NFAT activity to calcineurin activity; and;
screening and identifying novel therapeutic compounds.

### Claim 19 (depends on 18)

The method of claim 18, wherein the wherein NFAT phosphorylation or dephosphorylation state is a measure of NFAT activity.

### Claim 20 (depends on 18)

The method of claim 18, wherein an NFAT molecule comprises an NFAT polynucleotide, oligonucleotide, peptide, polypeptide, mutants, variants, fragments or combinations thereof.

### Claim 21 (depends on 18)

The method of claim 18, wherein the method is a high-throughput assay.

### Claim 22 (depends on 18)

A method of treating a disease or disorder characterized by proteinuria comprising administering to a patient in need thereof, an effective amount of an agent whereby the agent modulates NFAT activity and/or an agent identified by the method of claim 18.

### Claim 23 (depends on 22)

The method of claim 22, wherein the disease or disorder characterized by proteinuria comprising: glomerular diseases, membranous glomerulonephritis, focal segmental glomerulonephritis, minimal change disease, nephrotic syndromes, pre-eclampsia, eclampsia, kidney lesions, collagen vascular diseases, stress, strenuous exercise, benign orthostatic (postural) proteinuria, focal segmental glomerulosclerosis (FSGS), IgA nephropathy, IgM nephropathy, membranoproliferative glomerulonephritis, membranous nephropathy, sarcoidosis, Alport's syndrome, diabetes mellitus, kidney damage due to drugs, Fabry's disease, infections, aminoaciduria, Fanconi syndrome, hypertensive nephrosclerosis, interstitial nephritis, Sickle cell disease, hemoglobinuria, multiple myeloma, myoglobinuria, Wegener's Granulomatosis or Glycogen Storage Disease Type 1.

### Claim 24 (depends on 18)

A method of treating an immune-related disease or disorder comprising administering to a patient in need thereof, an effective amount of an agent whereby the agent modulates NFAT activity and/or an agent identified by the method of claim 18.

### Claim 25 (depends on 24)

The method of claim 24, wherein an immune-related disease comprises: acute immune diseases, chronic immune diseases, autoimmune diseases, inflammation, tissue or organ transplant graft rejections or graft-versus-host disease.

### Claim 26

A composition comprising at least one agent wherein the agent modulates NFAT expression, function or activity in vivo.

### Claim 27

A composition comprising a therapeutically effective amount of at least one agent which modulates expression, function or activity of transient receptor potential cation channels (TRPC) in vivo.

### Claim 28 (depends on 27)

The composition of claim 27, wherein the at least one agent decreases expression of one or more TRPCs in vivo as compared to a normal control.

### Claim 29

A method of treating kidney diseases or disorders in a patient, comprising administering to a patient in need thereof, a therapeutically effective amount of at least one agent which modulates expression, function or activity of at least one TRPC as compared to a normal control, and;
treating a kidney disease or disorder.

### Claim 30 (depends on 29)

The method of claim 29, wherein the expression, activity or function of a TRPC is measured by measuring intracellular Ca2+ levels, activation of calcineurin, phospphoryltaion or dephosphorylation of synaptopodin, interaction of synaptopodin with 14-3-3 proteins or cathepsin L cleavage.
